2026-04-17T06:31:51Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1931252025-12-05T12:34:37Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Marco, Carla author Simó, Marta author Alemany, Montse author Casasnovas, Carlos author Domínguez, Raúl author Vilariño, Noelia author Calvo, Mariona author Martín Liberal, Juan author Brenes, Jesús author Sabater Riera, Joan author Bruna, Jordi author Velasco, Roser author 2023-02-06T08:56:14Z 2023-02-06T08:56:14Z 2022-12-24 2023-02-02T09:15:29Z Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective chart review of the electronic medical records between 1 September 2017 and 2022. We report the clinical features, presentation forms, diagnostic workflows, general management and outcomes of six patients who received ICIs for different solid organ malignancies and developed an irMG frequently overlapping with immune-related myocarditis and/or myositis. The aim of the article is to describe the clinical features, treatment and outcomes of this challenging and potentially life-threating syndrome, comparing our data with those described in the literature. Differences between irMG and classic MG are highlighted. Malalties neuromusculars Malalties immunitàries Neurotoxicologia Neuromuscular diseases Immunologic diseases Neurotoxicology Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series